D3L-001

· D3 Bio (Wuxi) Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for D3L-001, covering 2026-03-13 to 2026-03-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors [Phase 1]